Natco Pharma shares rise 5% after filing for USFDA approval for a generic cancer drug

Posted by on



Natco Pharma shares rose nearly 5% to Rs 1,569 on BSE.
The increase followed the submission of a product application to the US FDA.
The application is for a generic version of Novartis' Tabrecta.
The submission includes an abbreviated new drug application with a paragraph IV certification.

Comments

Post a Comment